| Year |
Citation |
Score |
| 2022 |
West J, Robertson-Tessi M, Anderson ARA. Agent-based methods facilitate integrative science in cancer. Trends in Cell Biology. PMID 36404257 DOI: 10.1016/j.tcb.2022.10.006 |
0.34 |
|
| 2022 |
Strobl MAR, Gallaher J, West J, Robertson-Tessi M, Maini PK, Anderson ARA. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Communications Medicine. 2: 46. PMID 35603284 DOI: 10.1038/s43856-022-00110-x |
0.435 |
|
| 2022 |
Gatenbee CD, Baker AM, Schenck RO, Strobl M, West J, Neves MP, Hasan SY, Lakatos E, Martinez P, Cross WCH, Jansen M, Rodriguez-Justo M, Whelan CJ, Sottoriva A, Leedham S, et al. Immunosuppressive niche engineering at the onset of human colorectal cancer. Nature Communications. 13: 1798. PMID 35379804 DOI: 10.1038/s41467-022-29027-8 |
0.418 |
|
| 2021 |
West J, Schenck RO, Gatenbee C, Robertson-Tessi M, Anderson ARA. Normal tissue architecture determines the evolutionary course of cancer. Nature Communications. 12: 2060. PMID 33824323 DOI: 10.1038/s41467-021-22123-1 |
0.493 |
|
| 2020 |
Strobl MAR, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown JS, Gatenby RA, Maini PK, Anderson ARA. Turnover modulates the need for a cost of resistance in adaptive therapy. Cancer Research. PMID 33172930 DOI: 10.1158/0008-5472.CAN-20-0806 |
0.434 |
|
| 2020 |
West J, You L, Zhang J, Gatenby RA, Brown JS, Newton PK, Anderson ARA. Towards multi-drug adaptive therapy. Cancer Research. PMID 31948939 DOI: 10.1158/0008-5472.Can-19-2669 |
0.573 |
|
| 2019 |
West JB, Dinh MN, Brown JS, Zhang J, Anderson AR, Gatenby RA. Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30992299 DOI: 10.1158/1078-0432.Ccr-19-0006 |
0.382 |
|
| 2019 |
West J, Newton PK. Cellular interactions constrain tumor growth. Proceedings of the National Academy of Sciences of the United States of America. PMID 30674661 DOI: 10.1073/Pnas.1804150116 |
0.627 |
|
| 2018 |
West J, Ma Y, Newton PK. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. Journal of Theoretical Biology. 455: 249-260. PMID 30048718 DOI: 10.1016/J.Jtbi.2018.07.028 |
0.608 |
|
| 2017 |
West JB, Newton PK. Chemotherapeutic dose scheduling based on tumor growth rates provide a case for low-dose metronomic high entropy therapies. Cancer Research. PMID 28986381 DOI: 10.1158/0008-5472.Can-17-1120 |
0.656 |
|
| 2016 |
West J, Hasnain Z, Macklin P, Newton PK. AN EVOLUTIONARY MODEL OF TUMOR CELL KINETICS AND THE EMERGENCE OF MOLECULAR HETEROGENEITY DRIVING GOMPERTZIAN GROWTH. Siam Review. Society For Industrial and Applied Mathematics. 58: 716-736. PMID 29937592 DOI: 10.1137/15M1044825 |
0.68 |
|
| 2016 |
West J, Hasnain Z, Mason J, Newton PK. The prisoner's dilemma as a cancer model. Convergent Science Physical Oncology. 2. PMID 29177084 DOI: 10.1088/2057-1739/2/3/035002 |
0.61 |
|
| Show low-probability matches. |
